One only has to look at the number of clinical trials to recognize that cell therapies are one of fastest growing areas in terms of cancer new product development.
Over the past several years we’ve seen many changes and improvements in continuous innovation regarding the development of CAR T cells.
There has been no shortage of novel ways to enhance their targeting, durability, efficacy, or ease of administration. Most of the early strategies have yet to translate into commercial products, but it remains an area an attractive area to investors hoping to repeat the returns seen with Juno and Kite as more competitors enter the field.
In the fifth post in our mini-series on novel approaches in the emerging immunometabolism niche, we’re looking at ways to metabolically reprogram CAR T cells, as well as what the future may hold for the next generation of CAR T cells in this context.
Like a postcard from one’s summer holiday, it’s an opportunity to offer a snapshot at a moment in time from our journey.
We were fortunate to have the opportunity to talk with a researcher who is actively at the forefront of this area. Dr Roddy O’Connor is working with Carl June along with various colleagues at the University of Pennsylvania, and he kindly spoke to BSB about his work.